{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:34:21Z","timestamp":1793208861592,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","award":["3150120001"],"award-info":[{"award-number":["3150120001"]}],"id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.compbiomed.2023.107591","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T11:58:30Z","timestamp":1697630310000},"page":"107591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis"],"prefix":"10.1016","volume":"167","author":[{"given":"Yin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-7093","authenticated-orcid":false,"given":"Xiaosheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiomed.2023.107591_bib1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2147\/CCID.S410723","article-title":"Construction and identification of an NLR-associated prognostic signature revealing the heterogeneous immune response in skin cutaneous melanoma","volume":"16","author":"Geng","year":"2023","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107591_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/medsci9040063","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med. Sci."},{"issue":"7","key":"10.1016\/j.compbiomed.2023.107591_bib3","first-page":"3229","article-title":"Current status of biological therapies for the treatment of metastatic melanoma","volume":"36","author":"Tang","year":"2016","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107591_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"40","key":"10.1016\/j.compbiomed.2023.107591_bib5","doi-asserted-by":"crossref","first-page":"27714","DOI":"10.1074\/jbc.M113.532432","article-title":"Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells","volume":"289","author":"Lidsky","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.compbiomed.2023.107591_bib6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.compbiomed.2023.107591_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.compbiomed.2023.107591_bib9","article-title":"Earlier appears better for immunotherapy in melanoma","author":"O'Leary","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107591_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006454","article-title":"High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis","volume":"11","author":"Jung","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107591_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107591_bib12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107591_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"issue":"26","key":"10.1016\/j.compbiomed.2023.107591_bib14","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107591_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107591_bib16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6257","key":"10.1016\/j.compbiomed.2023.107591_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107591_bib18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107591_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"168","author":"Hugo","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.compbiomed.2023.107591_bib20","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1016\/j.csbj.2021.08.005","article-title":"Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma","volume":"19","author":"Liu","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12967-022-03436-1","article-title":"mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers","volume":"20","author":"Cheng","year":"2022","journal-title":"J. Transl. Med."},{"issue":"1\u20132","key":"10.1016\/j.compbiomed.2023.107591_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"issue":"6322","key":"10.1016\/j.compbiomed.2023.107591_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.compbiomed.2023.107591_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.03.068","article-title":"Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment","author":"Jiang","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107591_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107591_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","article-title":"Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade","volume":"5","author":"Nathanson","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.compbiomed.2023.107591_bib28","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.compbiomed.2023.107591_bib29","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107591_bib30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/bioinformatics\/bts022","article-title":"Surrogate variable analysis using partial least squares (SVA-PLS) in gene expression studies","volume":"28","author":"Chakraborty","year":"2012","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.compbiomed.2023.107591_bib31","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107591_bib32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.compbiomed.2023.107591_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinf."},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107591_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"issue":"11","key":"10.1016\/j.compbiomed.2023.107591_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nmeth.4463","article-title":"SCENIC: single-cell regulatory network inference and clustering","volume":"14","author":"Aibar","year":"2017","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","article-title":"Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome Atlas","volume":"23","author":"Knijnenburg","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12967-022-03355-1","article-title":"DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls","volume":"20","author":"Song","year":"2022","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107591_bib38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.compbiomed.2023.107591_bib39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.05005","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","volume":"4","author":"Agarwal","year":"2015","journal-title":"Elife"},{"issue":"D1","key":"10.1016\/j.compbiomed.2023.107591_bib40","doi-asserted-by":"crossref","first-page":"D222","DOI":"10.1093\/nar\/gkab1079","article-title":"miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions","volume":"50","author":"Huang","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"7172","key":"10.1016\/j.compbiomed.2023.107591_bib41","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.compbiomed.2023.107591_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. Roy. Stat. Soc. B"},{"issue":"19","key":"10.1016\/j.compbiomed.2023.107591_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197295","article-title":"Role of human leukocyte antigen system as A predictive biomarker for checkpoint-based immunotherapy in cancer patients","volume":"21","author":"Sabbatino","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107591_bib44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00262-022-03282-6","article-title":"PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20600-7","article-title":"Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy","volume":"12","author":"Somasundaram","year":"2021","journal-title":"Nat. Commun."},{"issue":"Suppl","key":"10.1016\/j.compbiomed.2023.107591_bib46","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.semcancer.2015.03.005","article-title":"Genomic instability in human cancer: molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition","volume":"35","author":"Ferguson","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107591_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab202","article-title":"DITHER: an algorithm for defining IntraTumor heterogeneity based on EntRopy","volume":"22","author":"Li","year":"2021","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.compbiomed.2023.107591_bib48","first-page":"1","article-title":"TP53 mutations promote immunogenic activity in breast cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"Journal of Oncology"},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107591_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001388","article-title":"MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination","volume":"9","author":"Wu","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.compbiomed.2023.107591_bib50","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.21037\/jtd.2020.04.18","article-title":"Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival","volume":"12","author":"Amanam","year":"2020","journal-title":"J. Thorac. Dis."},{"issue":"269","key":"10.1016\/j.compbiomed.2023.107591_bib51","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"12","key":"10.1016\/j.compbiomed.2023.107591_bib52","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1021\/acsbiomaterials.2c00950","article-title":"Enhanced immunogenic cell death by apoptosis\/ferroptosis hybrid pathway potentiates PD-L1 blockade cancer immunotherapy","volume":"8","author":"Jeong","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107591_bib53","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.compbiomed.2023.107591_bib54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2012.00167","article-title":"How does the kinase Lck phosphorylate the T cell receptor? Spatial organization as a regulatory mechanism","volume":"3","author":"Rossy","year":"2012","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib55","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1038\/s41598-019-41660-w","article-title":"Upregulation of NDRG1 predicts poor outcome and facilitates disease progression by influencing the EMT process in bladder cancer","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107591_bib56","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/jnci\/djab222","article-title":"NDRG1 in aggressive breast cancer progression and brain metastasis","volume":"114","author":"Villodre","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"37","key":"10.1016\/j.compbiomed.2023.107591_bib57","doi-asserted-by":"crossref","first-page":"11583","DOI":"10.1073\/pnas.1503683112","article-title":"NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability","volume":"112","author":"Croessmann","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107591_bib58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0006-291X(03)00942-2","article-title":"Identification of NDRG1 as an early inducible gene during in vitro maturation of cultured mast cells","volume":"306","author":"Taketomi","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.compbiomed.2023.107591_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","article-title":"DNA methylation and cancer","volume":"70","author":"Kulis","year":"2010","journal-title":"Adv. Genet."},{"key":"10.1016\/j.compbiomed.2023.107591_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107591_bib61","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a032771","article-title":"Mechanistic insights into MicroRNA-mediated gene silencing","volume":"11","author":"Duchaine","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"Pt 1","key":"10.1016\/j.compbiomed.2023.107591_bib62","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.semcancer.2019.03.004","article-title":"The role of SOX family members in solid tumours and metastasis","volume":"67","author":"Grimm","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107591_bib63","first-page":"1354","article-title":"Biological effects of BMP7 on small-cell lung cancer cells and its bone metastasis","volume":"53","author":"Shen","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12964-021-00737-8","article-title":"The emerging role of the KCTD proteins in cancer","volume":"19","author":"Angrisani","year":"2021","journal-title":"Cell Commun. Signal."},{"issue":"11","key":"10.1016\/j.compbiomed.2023.107591_bib65","doi-asserted-by":"crossref","first-page":"9498","DOI":"10.1002\/jcb.27266","article-title":"Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt\/beta-catenin pathway in pancreatic cancer cells","volume":"119","author":"Cao","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib66","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1186\/s12885-019-6161-8","article-title":"FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112506","article-title":"BAP1 antagonizes WWP1-mediated transcription factor KLF5 ubiquitination and inhibits autophagy to promote melanoma progression","volume":"402","author":"Jia","year":"2021","journal-title":"Exp. Cell Res."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib68","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13046-018-0933-x","article-title":"Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb","volume":"37","author":"D'Aguanno","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107591_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214073","article-title":"GDF11 upregulation independently predicts shorter overall-survival of uveal melanoma","volume":"14","author":"Liu","year":"2019","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.compbiomed.2023.107591_bib70","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1002\/cam4.3545","article-title":"Identification of key genes and pathways for melanoma in the TRIM family","volume":"9","author":"Xia","year":"2020","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107591_bib71","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2326-6066.CIR-15-0255","article-title":"Altered expression and splicing of ESRP1 in malignant melanoma correlates with epithelial-mesenchymal status and tumor-associated immune cytolytic activity","volume":"4","author":"Yao","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.compbiomed.2023.107591_bib72","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41419-022-05078-z","article-title":"KIT promotes tumor stroma formation and counteracts tumor-suppressive TGFbeta signaling in colorectal cancer","volume":"13","author":"Kucukkose","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.compbiomed.2023.107591_bib73","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3389\/fimmu.2018.01414","article-title":"Interferon signaling is frequently downregulated in melanoma","volume":"9","author":"Alavi","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.compbiomed.2023.107591_bib74","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1084\/jem.20160553","article-title":"Egr2 and 3 control adaptive immune responses by temporally uncoupling expansion from T cell differentiation","volume":"214","author":"Miao","year":"2017","journal-title":"J. Exp. Med."},{"issue":"21","key":"10.1016\/j.compbiomed.2023.107591_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd7455","article-title":"Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells","volume":"7","author":"Guo","year":"2021","journal-title":"Sci. Adv."},{"issue":"22","key":"10.1016\/j.compbiomed.2023.107591_bib76","doi-asserted-by":"crossref","first-page":"8498","DOI":"10.1002\/cam4.3481","article-title":"Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma","volume":"9","author":"Jiang","year":"2020","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107591_bib77","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s43856-023-00243-7","article-title":"Development and validation of an integrative pan-solid tumor predictor of PD-1\/PD-L1 blockade benefit","volume":"3","author":"Tomlins","year":"2023","journal-title":"Commun. Med."},{"issue":"8","key":"10.1016\/j.compbiomed.2023.107591_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082453","article-title":"Role of mTOR signaling in tumor microenvironment: an overview","volume":"19","author":"Conciatori","year":"2018","journal-title":"Int. J. Mol. Sci."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482523010569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482523010569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:58:06Z","timestamp":1793206686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482523010569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":78,"alternative-id":["S0010482523010569"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107591","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying biomarkers associated with immunotherapy response in melanoma by multi-omics analysis","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107591"}}